Going from $4.9 million to $18.7 million in operating cash flow in a single year isn’t a rounding error. It’s the kind of number that rewrites the health report on a business entirely.
You can decide whether the cash jump, the record EBITDA quarter, and the $10 million buyback make this digital health platform worth prescribing a position in right now.
Insider Access (Sponsored)
Bloomberg is calling Elon Musk's upcoming SpaceX IPO "the biggest listing of ALL TIME."
But here's the thing - most investors will be locked out until AFTER it goes public.
Not you.
I've found a 'backdoor' that lets everyday Americans grab a pre-IPO stake in SpaceX right now.
Click Here for the FREE "SpaceX" Ticker
The Quarter That Turned a Cash Flow Story Into Something Worth Acting On
OptimizeRx Corp (NASDAQ: OPRX) just posted a quarter that makes you read the business differently.
Operating cash flow increased over a twelve-month period. Adjusted EBITDA hit a record and nearly doubled the estimate.
EPS came in at $0.51 against a $0.24 estimate. That’s not a beat. That’s a different company than the one analysts had in their models.
The gross margin was 74.8% in Q4, up from 68.1% the year before. Management guided margins back toward the mid-60s for 2026, but the cash that came with Q4 is already in the bank.
That part isn’t changing.
Operating cash flow $18.7M vs $4.9M prior year: Nearly four times in one year. That’s the number that rewrites the story.
EPS $0.51 vs $0.24 estimate: Doubled the estimate on the bottom line. You don’t get that from accounting tricks.
Adjusted EBITDA record quarter: Management guided low, and the business ran well over it.
The cash flow isn’t a forecast. It already happened.
The $10 million buyback tells you management is putting money behind what they just delivered.
Action: Start with 15% if shares hold above $24 on normal volume. If price slides toward $21, cut in half and wait for a reclaim above $24.50 before adding more.
Market Alert (Sponsored)
From thousands of stocks, only five stood out as having the best chance to gain +100% or more in the months ahead.
A newly released 5 Stocks Set to Double special report reveals all five tickers — free for a limited time.
While future results can’t be guaranteed, previous editions of this report delivered gains of +175%, +498%, and even +673%¹.
The newest picks could follow a similar path.
This free opportunity expires at MIDNIGHT TONIGHT.
Get the free report here
*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.
The Subscription Shift Is What Could Make This Stick
The cash flow jump is the headline. But the reason it could keep happening is a shift in how the business earns revenue.
OptimizeRx is moving toward a subscription model through its DAAP platform. That means recurring, predictable income instead of one-off pharma campaign deals that reset every quarter.
Right now, the shift is creating a speed bump. Clients are signing shorter contracts while they figure out the new model.
That’s why 2026 revenue guidance came in flat at $109 million to $114 million. It’s not a growth story this year. It’s the setup for when the subscription base is actually built out.
DAAP subscription model in motion: Recurring revenue sticks around. One-off campaign revenue doesn’t. You want to be positioned before the mix tips.
Shorter contracts near-term: Temporary drag while clients adjust. Once they renew on the subscription model, they tend to stay longer.
Flat 2026 guidance $109M-$114M: This is management being conservative on purpose. They have a habit of guiding low and delivering above it.
Most people see flat guidance and move on. That’s the window where the setup makes sense.
Action: Net revenue retention is sitting at 116%, which means existing clients are already spending more.
If management signals subscription is now above 50% of contracted revenue, that is your signal to add.
If managed services stay near zero and subscription uptake stays slow, the flat guidance is not conservative. It is accurate, and you hold off on adding.
Hidden Income (Sponsored)
While President Trump's official salary is $400,000 per year... his tax returns reveal he's been collecting up to $250,000 PER MONTH from one hidden source.
Until recently, most Americans couldn't touch the type of investment that makes up this investment.
But thanks to Executive Order 14330, that just changed. If you love investing in disruptive new companies...
Discover how to invest in the fund Trump uses to collect this income
What the Buyback Is Really Saying About the Business
A $10 million buyback from a company sitting on $23.4 million in cash and carrying $26.3 million in debt is not a casual decision.
Management looked at where the stock was trading and decided buying their own shares was the best use of cash available. That’s a specific bet on the business being worth more than the price tag.
It also matters that the buyback is being paid for by the cash the business just generated, not from reserves or borrowed money.
That’s a meaningful difference. It means the operation is healthy enough to fund its own repurchase program during a year where revenue isn’t growing.
$10M buyback funded by operations: Not debt, not reserves. The business earned the cash, and management chose to spend it buying the stock back.
Management buying their own stock: This is as direct a signal as you get that they think the price is too low.
Management earned the cash and bought the stock with it. You can follow or wait for someone else to figure it out.
Action: Management said they will use free cash flow to pay down debt first and repurchase shares opportunistically.
That means the buyback will not be aggressive in the near term. Watch the Q1 cash balance update.
If cash holds above $20M after a debt payment, the buyback program is still active, and you stay in.
If cash drops below $15M, the buyback gets shelved, and the thesis weakens meaningfully.
How OPRX Looks Next to Its Digital Health Peers
Most digital health stocks are still trying to dig out from a rough couple of years.
OPRX isn’t starting from a stretched valuation. It just delivered a record EBITDA quarter, while the stock is still priced like the improvement hasn’t happened yet.
Compare that to peers that are still burning through cash, missing estimates, and issuing new shares to stay afloat. OPRX just showed real cash generation, a buyback, and a record profitability quarter all at once.
That combination is genuinely uncommon in this part of the market right now.
Record EBITDA while peers still miss: Most of the sector is still working toward profitability. OPRX just posted a record quarter on the number that matters most.
Cash generation vs cash burning peers: Going from $4.9M to $18.7M in operating cash flow puts OPRX in a different tier than most names in digital health.
Buying back stock while peers issue new shares: Issuing shares dilutes your ownership. Buying them back does the opposite. That divergence matters more than it sounds.
When one name in a struggling sector posts cash generation, a buyback, and record profitability in the same quarter, it tends to stand out for a reason.
Action: OPRX holding while peers fall is your signal to add 15%. Underperforming peers and dropping below $22.50 for more than one session means trim half and reset.
The Risks Are Real, but at Least They’re Visible
The most important thing to understand about the risk here: the 74.8% gross margin in Q4 is not what the business will run at going forward.
Management guided the mid-60s for 2026, which means Q4 was partly driven by a favorable revenue mix that won’t show up every quarter. If you’re betting on 74% margins continuing, you’re modeling the wrong business.
The real question is whether OPRX can still generate solid cash at normalized margins.
At 64-66% gross margins with the cost discipline Q4 showed, the math holds. The ceiling is lower than Q4 suggested, but the floor is still there.
Margins guide to mid-60s for 2026: Q4 was unusually strong on margins due to channel mix. Underwrite this at 64-66%, not 74%.
Shorter client contracts create near-term drag: Some clients are in wait-and-see mode on the subscription transition, and that friction could extend into the first half of 2026.
$23.4M cash vs $26.3M debt: The balance sheet is tight. If cash generation softens, the buyback pace slows too.
At least you can see it coming. That’s more useful than a risk hiding in the fine print.
Action: The debt maturity was extended to October 2027, which removes a near-term pressure point. Your hard stop is $18.7M in operating cash flow becoming $10M or less in 2026.
Trivia: What was the largest sports contract in history when Shohei Ohtani signed with the Dodgers in 2023?
The Operating Leverage Is Real and Doesn’t Disappear When Q4 Does
Q4 proved one thing above everything else: this business can convert revenue into cash when it’s running well.
The question isn’t whether Q4 repeats exactly. It’s whether the underlying machine that produced $18.7 million in cash flow is built to last or just got lucky.
The answer is mostly built to last. Revenue grew while costs stayed flat. Margins expanded. Cash conversion improved sharply.
Heading into 2026, the company has a buyback running, a subscription transition in progress, and a leaner operation than it had a year ago.
Revenue grew, costs didn’t: That’s operating leverage in plain English. Q4 showed the business can scale without proportionally growing its cost base.
Subscription model builds over time: Each client that moves to DAAP adds to a pool of recurring revenue that doesn’t reset every campaign cycle.
Cash flow creates real options: With $18.7M in operating cash flow, the business can invest, buy back shares, and pay down debt at the same time. That’s flexibility most small-cap names don’t have.
The leverage is real. The transition is happening. The buyback is running.
Position before the next print confirms it or doesn’t.
Action: Revenue per FTE hit $839K in 2025 vs $701K in 2024. The business is generating more output per dollar of headcount without adding staff.
If that figure keeps climbing, operating leverage is compounding, and you add aggressively.
If revenue per FTE drops back below $750K, cost creep is returning, and the efficiency story is losing its edge.
Final Word: The Numbers Changed. The Price Hasn’t Caught Up Yet.
OptimizeRx isn’t pitching a turnaround. It already delivered one.
Cash flow nearly quadrupled. EBITDA hit a record. EPS doubled the estimate. The business is healthier than the stock price reflects right now.
Yes, the near term has friction.
Flat revenue guidance, clients adjusting to the subscription model, and margins normalizing from an exceptional quarter.
But the cost structure is leaner, the cash generation is real, and management just told you with a buyback exactly where they think the stock should be trading.
Watch the cash flow, watch the subscription build, and let the results write the prescription.
Setup Scorecard
Entry Window: $24. Hold above it on normal volume, and the entry is clean.
Catalyst Watch: Q1 2026 results, DAAP subscription updates, guidance revisions. Those three move this fastest.
Upside Setup: Subscription model maturing plus operating leverage equals sustained cash generation. Each buyback makes future EPS beats hit harder.
Downside Cushion: Conservative guidance, confirmed leverage, and an active buyback limit damage from a softer quarter.
What Moves It Next: Cash flow, mid-60s margins, subscription growth. All three holding means the thesis is intact. One breaks materially, and that’s your signal.
That's our coverage for today; thanks for reading! Reply to this email with feedback or any value names you want me to check out.
Best Regards,
—Noah Zelvis
Undervalued Edge
